Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$45.25 USD

45.25
952,397

-0.17 (-0.37%)

Updated Aug 12, 2024 04:00 PM ET

After-Market: $45.26 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that display a bullish run. Stocks seeing price strength have a high chance of carrying the momentum forward.

Henry Schein Banks on Dental Consumable Amid Coronavirus Woes

by Zacks Equity Research

Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.

Henry Schein Medical to Expand in Telemedicine With VisualDx

by Zacks Equity Research

Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.

QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results

by Zacks Equity Research

Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.

Hologic Expands Product Portfolio With New Ultrasound System

by Zacks Equity Research

Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.

Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes

by Zacks Equity Research

Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.

Medtronic Launches User-Friendly Insulin Infusion Set in US

by Zacks Equity Research

Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.

LabCorp Launches At-Home Coronavirus Test Collection Kit

by Zacks Equity Research

LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.

Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge

by Zacks Equity Research

Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.

Align Technology's Rollouts Aid Amid Procedural Deferrals

by Zacks Equity Research

Align Technology's (ALGN) new virtual solutions ensure continuity of care amid pandemic.

Thermo Fisher Stock Rises on Solid Q2 Growth Expectation

by Zacks Equity Research

Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.

IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests

by Zacks Equity Research

IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.

Boston Scientific's (BSX) ICM System Receives FDA Approval

by Zacks Equity Research

Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.

Trina Mukherjee headshot

3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears

by Trina Mukherjee

Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.

Myriad Genetics Unveils New Home DNA Sample Collection Kit

by Zacks Equity Research

Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.

Manaswita Ghosh Dutta headshot

3 AI Healthcare Stocks to Ride Out the Coronavirus Resurgence

by Manaswita Ghosh Dutta

Efficient use of data by artificially intelligent applications has put into the spotlight their urgent need in the healthcare domain.

QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses

by Zacks Equity Research

QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.

LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D

by Zacks Equity Research

This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.

Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe

by Zacks Equity Research

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.

Myriad Genetics' myPath Melanoma Proved Superior Per New Study

by Zacks Equity Research

Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.

Here's Why You Should Hold on to Illumina Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D

by Zacks Equity Research

The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.

Medtronic's DBS System With BrainSense Technology Gets FDA Nod

by Zacks Equity Research

Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be upbeat about ResMed (RMD) owing to its strong emphasis on product development and consistent high demand for its critical care products.